Lantheus (NASDAQ:LNTH) Reaches New 52-Week High – Should You Buy?

Lantheus Holdings, Inc. (NASDAQ:LNTH) hit a new 52-week high during trading on Wednesday . The company traded as high as $107.99 and last traded at $105.03, with a volume of 1423657 shares trading hands. The stock had previously closed at $104.67.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. William Blair restated an “outperform” rating on shares of Lantheus in a report on Tuesday, March 17th. Citizens Jmp increased their price target on shares of Lantheus from $85.00 to $115.00 and gave the company a “market outperform” rating in a research report on Friday, May 8th. Truist Financial reissued a “buy” rating and set a $115.00 price objective (up from $98.00) on shares of Lantheus in a research note on Monday, May 11th. Jefferies Financial Group restated a “buy” rating and set a $110.00 price objective on shares of Lantheus in a research report on Tuesday, March 17th. Finally, Wall Street Zen lowered Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Lantheus presently has an average rating of “Moderate Buy” and an average price target of $101.86.

Lantheus Stock Up 0.7%

The firm’s 50 day moving average is $92.89 and its two-hundred day moving average is $78.06. The stock has a market cap of $6.77 billion, a price-to-earnings ratio of 25.04 and a beta of -0.03. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.25 by $0.21. The company had revenue of $377.33 million for the quarter, compared to analysts’ expectations of $354.48 million. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The firm’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period last year, the company earned $1.53 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, sell-side analysts predict that Lantheus Holdings, Inc. will post 4.39 EPS for the current year.

Institutional Trading of Lantheus

Several hedge funds and other institutional investors have recently bought and sold shares of LNTH. Western Wealth Management LLC purchased a new position in shares of Lantheus during the 1st quarter worth $25,000. Osterweis Capital Management Inc. purchased a new stake in shares of Lantheus in the second quarter valued at $36,000. Smartleaf Asset Management LLC increased its stake in Lantheus by 63.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 197 shares during the last quarter. Bessemer Group Inc. increased its stake in Lantheus by 221.2% in the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 354 shares during the last quarter. Finally, Parallel Advisors LLC lifted its position in Lantheus by 122.6% during the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 298 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.